A Novel DNA Aptamer for Dual Targeting of Polymorphonuclear Myeloid-derived Suppressor Cells and Tumor Cells
Liu H, Mai J, Shen J, Wolfram J, Li Z, Zhang G, Xu R, Li Y, Mu C, Zu Y, Li X, Lokesh GL, Thiviyanathan V, Volk DE, Gorenstein DG, Ferrari M, Hu Z, Shen H. Theranostics. 2018 Jan 1;8(1):31-44. PubMed
Nucleolin-Targeting AS1411-Aptamer-Modified Graft Polymeric Micelle with Dual pH/Redox Sensitivity Designed To Enhance Tumor Therapy through the Codelivery of Doxorubicin/TLR4 siRNA and Suppression of Invasion
Yang S, Ren Z, Chen M, Wang Y, You B, Chen W, Qu C, Liu Y, Zhang X. Mol Pharm. 2018 Jan 2;15(1):314-325. PubMed
RAGE-aptamer Attenuates the Growth and Liver Metastasis of Malignant Melanoma in Nude Mice
Nakamura N, Matsui T, Ishibashi Y, Sotokawauchi A, Fukami K, Higashimoto Y, Yamagishi SI. Mol Med. 2017 Nov 6;23. PubMed
The “Janus face” of the thrombin binding aptamer: Investigating the anticoagulant and antiproliferative properties through straightforward chemical modifications
Esposito V, Russo A, Amato T, Vellecco V, Bucci M, Mayol L, Russo G, Virgilio A, Galeone A. Bioorg Chem. 2017 Nov 15;76:202-209. PubMed
Cholesterol-GalNAc Dual Conjugation Strategy for Reducing Renal Distribution of Antisense Oligonucleotides
Wada F, Yamamoto T, Ueda T, Sawamura M, Wada S, Harada-Shiba M, Obika S. Nucleic Acid Ther. 2018 Feb;28(1):50-57. PubMed
Structural properties and gene-silencing activity of chemically modified DNA-RNA hybrids with parallel orientation
Habibian M, Yahyaee-Anzahaee M, Lucic M, Moroz E, MartĂn-Pintado N, Di Giovanni LD, Leroux JC, Hall J, GonzĂ¡lez C, Damha MJ. Nucleic Acids Res. 2018 Jan 24. PubMed
Modulation of BACE1 activity by chemically modified aptamers
Gasse C, Zaarour M, Noppen S, Abramov M, Marlière P, Liekens S, De Strooper B, Herdewijn P. Chembiochem. 2018 Jan 11. PubMed
A modular platform for targeted RNAi therapeutics
Kedmi R, Veiga N, Ramishetti S, Goldsmith M, Rosenblum D, Dammes N, Hazan-Halevy I, Nahary L, Leviatan-Ben-Arye S, Harlev M, Behlke M, Benhar I, Lieberman J, Peer D. Nat Nanotechnol. 2018 Jan 29. PubMed
Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer
Gibori H, Eliyahu S, Krivitsky A, Ben-Shushan D, Epshtein Y, Tiram G, Blau R, Ofek P, Lee JS, Ruppin E, Landsman L, Barshack I, Golan T, Merquiol E, Blum G, Satchi-Fainaro R. Nat Commun. 2018 Jan 2;9(1):16. PubMed
Nanotherapeutics for Gene Modulation that Prevents Apoptosis in the Brain and Fatal Neuroinflammation
Kim SS, Rait A, Garrido-Sanabria ER, Pirollo KF, Harford JB, Chang EH. Mol Ther. 2018 Jan 3;26(1):84-94. PubMed